Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: High body mass index (BMI) plays a key role in the development of colon cancer (CC). Our post-hoc analysis from the TOSCA trial analyzed the association between BMI and survival outcomes in terms of relapse-free survival (RFS) and overall survival (OS) in stage II/III CC patients.

Patients And Methods: Patients enrolled in the TOSCA trial between 2007-2013 with BMI data entered the study. The prognostic impact of BMI on survival outcomes was investigated through uni- and multivariable Cox regression analyses.

Results: Overall, 1455 patients with stage II/III CC patients were included. The median follow-up was of 61.5 months; 16.1% of patients relapsed, 11.2% died and 19.5% patients relapsed or died. No impact of BMI on RFS was detected at univariate or multivariable analyses. By univariate analysis for OS, a significantly impact of a BMI > 30 kg/m was reported (HR [>30 vs <25] 1.57, 95% CI 1.00-2.47, p = 0.049; HR [>30 vs <30] 1.55, 95% CI 1.01-2.37, p = 0.045). Multivariable analyses did not confirm this data. In the subgroup of stage III patients, a negative survival impact of BMI was found in univariate and multivariable models both for RFS and for OS.

Conclusions: In our study, obesity with BMI > 30 kg/m was an independent prognostic factor for RFS and OS in CC patients treated with adjuvant chemotherapy, regardless of its duration (3 or 6 months). However, the prognostic impact of adiposity and body composition measurement should be considered to better classify patients with high visceral fat and refine their risk assessment.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2023.01.004DOI Listing

Publication Analysis

Top Keywords

stage ii/iii
12
tosca trial
12
impact bmi
12
body mass
8
colon cancer
8
analysis tosca
8
bmi survival
8
survival outcomes
8
prognostic impact
8
patients relapsed
8

Similar Publications

Estimation of salivary protectin D1 in periodontitis patients with metabolic syndrome following non-surgical periodontal therapy.

Clin Oral Investig

September 2025

Department of Periodontics, Saveetha Dental College, Saveetha Institute of Medical and Technology Sciences, SIMATS, Saveetha University, Chennai, Tamil Nadu, India.

Objectives: This study aims to assess periodontal and biochemical parameters and evaluate the salivary Protectin D1 levels in periodontitis patients with and without metabolic syndrome after non-surgical periodontal therapy.

Materials And Methods: Forty patients were categorized into two groups: 20 patients in Group P (systemically healthy patients with stage II/III grade B periodontitis) and 20 patients in Group P+MS (patients with stage II/III grade B periodontitis and metabolic syndrome). Parameters including age, gender, height, weight, body mass index, waist circumference, socio-economic status, oral hygiene index (OHI), modified gingival index (MGI), probing pocket depth, clinical attachment levels, fasting blood glucose, HDL-c, total triglycerides, and blood pressure were recorded.

View Article and Find Full Text PDF

Curative-intent multimodality treatment-combining local treatments such as surgery or radiotherapy with systemic therapy-is the cornerstone of care in stage II-III non-small cell lung cancer (NSCLC). Since 2017, the systemic therapy backbones with multimodality treatment have undergone a dramatic transformation, driven by a series of pivotal, practice-changing clinical trials. Immunotherapy and targeted therapies, previously confined to the advanced/metastatic setting, are now firmly embedded in curative-intent regimens.

View Article and Find Full Text PDF

Prognostic impact and characteristics of ROS1 fusion in patients with surgically resected lung adenocarcinoma.

Lung Cancer

September 2025

Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, PR China. Electronic address:

Objective: We aimed to investigate the prognostic significance of ROS1 fusion in surgically resected lung adenocarcinoma (LUAD).

Materials And Methods: Consecutive patients who underwent complete resection and ROS1 testing between 2015 and 2020 were included. Propensity score matching (1:2) was applied to balance baseline characteristics.

View Article and Find Full Text PDF

Background: Neoadjuvant chemotherapy plus anti-programmed death (ligand)-1 (anti-PD-(L)1) inhibitors (chemoimmunotherapy) for early-stage nonsmall cell lung cancer (NSCLC) is under investigation, but differences in pathological response rates between patients who achieved objective responses after 2 versus 3-6 cycles remain unclear.

Methods: We retrospectively enrolled 481 stage II-III NSCLC patients who had 2-6 cycles of neoadjuvant chemoimmunotherapy followed by surgery (June 2018-February 2024). The primary outcomes compared the pathological response (pathological complete response [pCR] and major pathological response [MPR]) between the 2-cycle (n = 99) and 3-6-cycle (n = 382) groups in patients who achieved objective response as well as between objective response rate (ORR) and non-ORR groups.

View Article and Find Full Text PDF

Development of a new TNM staging system for poorly differentiated thyroid carcinoma: a multicenter cohort study.

Front Endocrinol (Lausanne)

September 2025

Department of General Surgery (Thyroid Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

Objective: Poorly differentiated thyroid cancer (PDTC) is a rare, heterogeneous carcinoma from follicular cells, characterized by poor differentiation, aggressive spread, and poor prognosis. Currently, there is no specific staging system for PDTC. This study aimed to develop a new TNM staging system tailored to PDTC for improved disease management.

View Article and Find Full Text PDF